We added the following clinical trials to Metastatic Trial Search for January 2026. To see all clinical trials, please visit Metastatic Trial Search.

ER/PR Positive Trials

• GTAEXS617 for Advanced HR+ HER2- Breast Cancer
• Elacestrant Compared to Elacestrant Plus a CDK4/6 Inhibitor for Advanced ER+, HER2- Breast Cancer
• AVZO-023 Plus Hormone Therapy and an Experimental CDK2 Inhibitor for Advanced HR+, HER2- Breast Cancer
• Dato-DXd for Advanced HR+, HER2- Breast Cancer
• Palazestrant and Ribociclib Compared to Letrozole and Ribociclib for Advanced ER+, HER2- Breast Cancer
• Preventing Mouth Sores Due to Dato-DXd With Dexamethasone Mouthwash for Advanced HR+, HER2- or Triple Negative Breast Cancer

Triple Negative Trials

• LY4175408 for Advanced Triple Negative Breast Cancer
• Cyclophosphamide, Axatilimab, and Retifanlimab for Advanced Triple Negative or Inflammatory Breast Cancer
• PQ203 Peptide Drug-Conjugate for Advanced Triple Negative Breast Cancer

Other Trials

• LY4337713 Radiopharmaceutical for Fibroblast Activation Protein (FAP)-Positive Advanced Breast Cancer
• The Sarah Nanotechnology System for Metastatic Breast Cancer

Last Modified on January 16, 2026